KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Tax Provisions (2023 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Tax Provisions for 3 consecutive years, with $20000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 185.71% year-over-year to $20000.0, compared with a TTM value of -$136000.0 through Dec 2025, up 87.94%, and an annual FY2025 reading of -$136000.0, up 87.93% over the prior year.
  • Tax Provisions was $20000.0 for Q4 2025 at Recursion Pharmaceuticals, up from $2000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $167000.0 in Q3 2024 and bottomed at -$4.1 million in Q4 2023.
  • Average Tax Provisions over 3 years is -$665750.0, with a median of -$78000.0 recorded in 2025.
  • Peak annual rise in Tax Provisions hit 185.71% in 2025, while the deepest fall reached 98.8% in 2025.
  • Year by year, Tax Provisions stood at -$4.1 million in 2023, then skyrocketed by 100.17% to $7000.0 in 2024, then skyrocketed by 185.71% to $20000.0 in 2025.
  • Business Quant data shows Tax Provisions for RXRX at $20000.0 in Q4 2025, $2000.0 in Q3 2025, and -$158000.0 in Q1 2025.